Signet Financial Management LLC Cuts Stock Holdings in GSK plc (NYSE:GSK)

Signet Financial Management LLC lessened its holdings in GSK plc (NYSE:GSK) by 12.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,412 shares of the pharmaceutical company’s stock after selling 1,334 shares during the quarter. Signet Financial Management LLC’s holdings in GSK were worth $318,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Sivia Capital Partners LLC boosted its stake in shares of GSK by 29.5% in the fourth quarter. Sivia Capital Partners LLC now owns 6,610 shares of the pharmaceutical company’s stock valued at $224,000 after buying an additional 1,507 shares in the last quarter. Enterprise Bank & Trust Co lifted its holdings in GSK by 3.0% in the fourth quarter. Enterprise Bank & Trust Co now owns 26,892 shares of the pharmaceutical company’s stock valued at $909,000 after acquiring an additional 791 shares during the period. Keystone Financial Planning Inc. boosted its position in shares of GSK by 3,660.9% during the 4th quarter. Keystone Financial Planning Inc. now owns 227,913 shares of the pharmaceutical company’s stock worth $7,708,000 after purchasing an additional 221,853 shares in the last quarter. Thomasville National Bank boosted its position in shares of GSK by 3.4% during the 4th quarter. Thomasville National Bank now owns 491,441 shares of the pharmaceutical company’s stock worth $16,621,000 after purchasing an additional 16,057 shares in the last quarter. Finally, Brookstone Capital Management grew its stake in shares of GSK by 19.8% during the 4th quarter. Brookstone Capital Management now owns 31,701 shares of the pharmaceutical company’s stock worth $1,072,000 after purchasing an additional 5,244 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GSK. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Monday. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Down 1.1 %

Shares of GSK stock opened at $32.71 on Tuesday. GSK plc has a 1 year low of $32.55 and a 1 year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The business has a 50 day moving average price of $34.30 and a 200 day moving average price of $38.12. The company has a market capitalization of $67.79 billion, a P/E ratio of 21.24, a P/E/G ratio of 1.52 and a beta of 0.63.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were given a $0.3928 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.80%. The ex-dividend date of this dividend was Friday, November 15th. GSK’s dividend payout ratio is currently 95.45%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.